CurrentAetnaPolicy 0302

Xerostomia: Selected Treatments

This policy governs coverage determinations for selected non-pharmacologic and device-based treatments for xerostomia (dry mouth) for Aetna members. It identifies interventions considered experimental/investigational and lists related billing codes and clinical background evidence summaries.

Policy Summary

PayerAetna

PolicyXerostomia: Selected Treatments

Policy CodePolicy 0302

Change TypeNo material change

Effective DateFeb 6, 2004

Next Review DateMar 14, 2024

Key ActionVerify medical necessity and coverage for listed CPT/HCPCS codes prior to performing or billing xerostomia interventions.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

>10experimental interventions

9Cochrane studies

366Cochrane participants

148RTOG 0537 randomized

399Acupuncture prevention RCT

02/06/2004

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria — Experimental / Investigational Interventions

inv-01: Experimental and Investigational

The following interventions are considered experimental and investigational because effectiveness has not been established:

Experimental/Investigational interventions: Includes electrical stimulation (e.g., Salitron System and Saliwell Crown), acupuncture, ALTENS, adipose tissue-derived mesenchymal stem cell therapy, fat grafting to salivary glands, hyperbaric oxygen, low-level laser/low-level light therapy (photo-biomodulation), transcutaneous electrical nerve stimulation (TENS), and Venalot Depot (coumarin plus troxerutin)

List is not all-inclusive

inv-02: Evidence synthesis for coverage considerations

Summary of evidence-based findings relevant to coverage decisions

Electrical stimulation (TENS/ALTENS/intra-oral electrostimulation): Evidence is mixed: small phase II and pilot studies reported increased salivary flow during stimulation and subjective improvements (Vijayan n=30; GenNarino case series n=6; pilot n=40) but systematic reviews/meta-analyses found insufficient or non-significant pooled effects for TENS on salivary flow and xerostomia symptoms; the phase III RTOG 0537 (ALTENS vs pilocarpine, n=148) did not find a significant difference in the primary patient-reported xerostomia endpoint at 9 months though ALTENS had fewer treatment-related toxicities; overall quality of evidence is low to moderate and larger definitive trials are needed.evidence mixed; not definitive

Chunks: 20,21,24,25,37

Acupuncture: Trials and systematic reviews provide low-quality and inconsistent evidence; some randomized trials show small increases in stimulated and unstimulated saliva and one large prevention RCT (Garcia et al., n=399) reported fewer and less severe radiation-induced xerostomia symptoms at 1 year for true acupuncture versus standard care, with variable results versus sham; adverse effects reported are mild and transient.evidence inconclusive; potential symptom benefit in some settings

Chunks: 18,22,29

Photo-biomodulation / Low-level light therapy (LLLT): Some randomized trials and systematic reviews/meta-analyses report short-term improvements in salivary flow with certain parameter ranges (infra-red wavelengths ~790–830 nm, power 30–120 mW, energy density <30 J/cm2), but trials are heterogeneous, at high risk of bias, and a randomized trial in primary Sjögren's (n=66) using an 808 nm protocol showed no benefit; overall evidence is suggestive but not definitive and outcomes on sustained quality-of-life benefit are not established.parameter-sensitive; evidence suggestive but not definitive

Chunks: 34,35

Topical sialogogue (malic acid 1% spray) and saliva substitutes: Small RCTs and meta-analyses report symptomatic improvement and increased stimulated and unstimulated saliva over short (2-week) courses for a 1% malic acid spray, while artificial saliva products reduce symptoms variably; long-term efficacy and safety (eg, effects on enamel) remain uncertain.evidence limited to short-term courses

Chunks: 39

Regenerative and surgical approaches (adipose-derived stem cells, fat grafting, submandibular gland transfer, hyperbaric oxygen): Preclinical and early-phase clinical data suggest potential for adipose-derived mesenchymal stem cells and fat grafting to affect salivary tissue, and small early trials of ASC transplantation report promising but limited results; submandibular gland transfer may maintain saliva production in selected patients but is performed at select centers and lacks widespread adoption or billing codes; hyperbaric oxygen has preliminary positive findings but requires confirmatory trials.experimental/preclinical/limited centers

Chunks: 27,49,42

inv-03: Evidence summaries relevant to coverage

Evidence summaries and implications for coverage decisions:

Amifostine for prevention of radiotherapy-induced xerostomia: Low-quality evidence suggests amifostine may reduce the risk of moderate-to-severe xerostomia at the end of radiotherapy and up to 3 months post-radiotherapy, but there is insufficient evidence of sustained benefit at 12 months; use is associated with increased adverse effects (eg, vomiting, hypotension, nausea, allergic reactions) and high cost — benefits must be weighed against toxicity and resource implications.effects observed up to 3 months; not proven at 12 months

Chunks: 42,44

Pilocarpine and other pharmacologic agents: Evidence is inconsistent or very low-quality for consistent benefit of pilocarpine and other pharmacologics across xerostomia outcomes; some safety signals (eg, increased sweating with pilocarpine) have been reported.safety signal: increased sweating (RR 2.98 reported in reviews)

Chunks: 42,44,49

Certain CPT, HCPCS and ICD-10 codes are specifically enumerated in this Clinical Policy Bulletin as not covered for the indications listed in the CPB. Providers should verify medical necessity and coverage prior to performing or billing these services, since submission of these codes for the CPB-listed indications may result in claim denials.

Fat grafting to salivary glands is described in the literature as a preclinical or early translational approach: co-culture and animal transplantation studies demonstrate differentiation of adipose-derived stem cells into salivary-gland-like tissue, but clinical evidence is absent and major clinical resources (including a systematic review and an UpToDate review) do not list fat grafting as a therapeutic option. Therefore this technique remains experimental and not established for routine patient care.

Systematic reviews and evidence summaries found insufficient evidence to determine the effects of numerous interventions (for example, biperiden plus pilocarpine, various Chinese medicines, bethanechol, artificial saliva as a disease‑modifying therapy, selenium, antiseptic mouth rinses, antimicrobial lozenges, polaprezinc, azulene rinse, and Venalot Depot). These therapies remain investigational pending higher-quality data.

This Clinical Policy Bulletin provides a partial, general description of plan or program benefits and is intended to assist in administering benefits. It is not a contract, does not constitute medical advice, and may be updated; providers should consult the full policy and plan documents for definitive coverage and authorization requirements.

Interventions explicitly listed as experimental and investigational in this bulletin are considered not established for effectiveness. As a result, these interventions are regarded as not medically necessary for the prevention or treatment of xerostomia for the indications covered by this CPB.

Systematic reviews and randomized trials evaluating transcutaneous electrical nerve stimulation (TENS/ALTENS) and related electrical stimulation approaches show heterogeneous results. A pooled analysis of six RCTs (369 participants) did not demonstrate a statistically significant benefit for TENS on salivary flow, and photo‑biomodulation (LLLT) trials and meta-analyses report short‑term increases in salivary flow but with high risk of bias and heterogeneity. Overall, the evidence lacks consistent, high‑quality demonstration of clinical benefit for electrical stimulation or related modalities.

A single randomized trial of intravenous amifostine closed early and was underpowered; it did not show a clear reduction in grade ≥2 xerostomia and was associated with higher rates of other toxicities (for example, increased vomiting, hypotension and fatigue). Given the limited sample size and increased non‑xerostomia adverse effects, this study does not provide definitive support for routine use of intravenous amifostine to prevent radiotherapy‑induced xerostomia.

Billing and Coding

Listed CPT CodesCPT

0552T	Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional.
15769	Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia).
15773	Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate.
15774	Each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure).
97810	Acupuncture.
97811	Acupuncture.
97812	Acupuncture.
97813	Acupuncture.
97814	Acupuncture.
99183	Physician or other qualified health care professional attendance and supervision of hyperbaric oxygen therapy, per session.

Listed HCPCS CodesHCPCS

E0755	Electronic salivary reflex stimulator (intraoral/noninvasive).
G0277	Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval.
S8948	Application of a modality (requiring constant provider attendance) to one or more areas; low-level laser; each 15 minutes.

Listed ICD-10 CodesICD-10

K11.7	Disturbance of salivary secretion (xerostomia).
R68.2	Dry mouth, unspecified.
T66.xx	Effects of radiation, unspecified [radiation-induced xerostomia].
Z92.3	Personal history of irradiation.

Provider Actions, Prior Authorization, and Documentation

Denial Risk

Evidence incompleteness may affect coverage

Evidence incompleteness may affect coverage decisions. Several trials (for example, RTOG 0537) had limited evaluable populations, incomplete data, or preliminary small-phase results; providers should be aware that such limitations can influence medical necessity determinations and coverage.

Incomplete or underpowered trials may lead to noncoverage or experimental classification.
When relying on trial evidence for novel therapies (e.g., ASC transplantation, amifostine), document trial limitations in the medical record.

Documentation Required

Suggested objective measures for documentation

Use objective, standardized measures to document salivary function when clinically assessing xerostomia and when requesting coverage for treatments. Preferred measures in the literature include unstimulated and stimulated whole saliva flow rates collected with timed, graduated collection methods.

Background and Context

Chronic xerostomia may result from autoimmune disease (for example, Sjögren's syndrome), medications, or therapeutic irradiation. It can cause difficulty with eating, swallowing and denture use, and it increases risk for dental caries, oral pain and infections. Management focuses on symptomatic relief (saliva substitutes, stimulants) and, for investigational regenerative or device‑based therapies, the evidence base remains limited; these factors inform the experimental/investigational designations in this bulletin.

Definitions and Terminology

Xerostomia — Definition

DefinitionDisturbance of salivary secretion resulting in dry mouth, susceptibility to dental caries and oral infections.

Common causesSjögren's syndrome, certain medications, therapeutic irradiation (radiation-induced xerostomia).

ImpactCan cause difficulty eating dry foods, swallowing, denture use, increased oral pain and frequent infections.

ALTENS

TermALTENS (Acupuncture-like transcutaneous electrical nerve stimulation)

Use in trialsUsed as a non-pharmacologic intervention for radiation-induced xerostomia (e.g., RTOG 0537 compared twice-weekly 20‑minute ALTENS sessions for 12 weeks vs pilocarpine).

Policy Dates and Revision History

2004-02-06effective_date

Policy became effective.

2023-05-08last_reviewLatest

Policy was last reviewed.

2024-03-14next_review_scheduled

Next policy review scheduled.

Policy Summary

PayerAetna

PolicyXerostomia: Selected Treatments

Policy CodePolicy 0302

Change TypeNo material change

Effective DateFeb 6, 2004

Next Review DateMar 14, 2024

Key ActionVerify medical necessity and coverage for listed CPT/HCPCS codes prior to performing or billing xerostomia interventions.

SourceLink

On This Page

Low-level light therapy (photobiomodulation) implications:

Meta-analyses demonstrate short-term increases in unstimulated salivary flow versus placebo (eg, SMD ~0.51 in some pooled analyses) but heterogeneity and high risk of bias limit confidence; long-term QOL benefits are not established and parameter standardization is lacking.

short-term benefit only

Transcutaneous electrical nerve stimulation (TENS/ALTENS) implications: Systematic reviews and pooled analyses report heterogeneous results with no consistent statistically significant pooled benefit; individual trials show mixed outcomes and parameter variability—high-quality, adequately powered RCTs are needed to establish efficacy and optimal parameters.heterogeneous results; parameter-dependent

Chunks: 37,25

Experimental interventions (stem cells, fat grafting, submandibular gland transfer, hyperbaric oxygen): Evidence from randomized and non-randomized early-phase studies is limited in size and quality; some interventions (eg, ASC transplantation, submandibular gland transfer) show promise in small cohorts but require confirmatory trials before widespread coverage; surgical gland transfer is specialized and not widely practiced.limited sample sizes and centers; confirmatory trials required

Chunks: 42,27,49

Unstimulated whole saliva (e.g., 5–10 minute low forced spitting method) with reported ml/min.

Stimulated whole saliva collection (e.g., electrical or citric acid stimulation) with reported ml/min.

Report collection method, timing relative to radiation or intervention, and baseline vs post-treatment values.

Documentation Required

Required clinical outcome documentation for experimental therapies

When experimental or investigational therapies are used (for example, stem cell transplantation, investigational pharmacologic agents, or procedures without established coding), clinical outcome documentation should include validated patient-reported outcomes and objective salivary measures, and report adverse events. Trial-reported outcome domains commonly include unstimulated/stimulated saliva flow, xerostomia questionnaires (e.g., XeQOLS), VAS for symptoms, and gland function assays.

Include baseline and serial post-treatment measurements (specify timepoints).
Include patient-reported xerostomia scales (e.g., XeQOLS) and symptom VAS scores.
Document any procedure- or drug-related adverse events and biopsy/imaging findings if obtained.

Note

Documentation note and administrative guidance

Refer to the full clinical policy bulletin for complete documentation requirements, coding guidance, and supplemental information. The excerpt does not specify prior authorization rules or step therapy in this portion; providers should verify plan-specific authorization and coding prior to billing.

Verify member benefits and prior authorization requirements with the payer before performing procedures.
Consult the full CPB for lists of CPT/HCPCS/ICD-10 codes noted as not covered for listed indications.
Maintain complete clinical records supporting medical necessity, including objective measures and trial rationale when applicable.

Step Therapy

No step therapy rules included in this extract

No step therapy rules are specified in the provided policy extract. There are no step-therapy sequences or mandatory conservative-first pathways stated here; however, conservative measures (salivary substitutes, sips of water, conventional pharmacologic agents) are commonly used first-line in practice before experimental or invasive interventions.

If a plan requires conservative therapy trials, document dates, agents used (e.g., salivary substitutes, pilocarpine), durations, and clinical response.
Absence of step therapy in this extract does not preclude plan-level or benefit-specific requirements; verify per member plan.

Evidence summaryRTOG 0537 (n=148) showed no significant difference in primary patient-reported xerostomia endpoint at 9 months versus pilocarpine; fewer toxicities reported with ALTENS but limited evaluable data (96/148).

LLLT / Photo-biomodulation

TermLLLT / Photo-biomodulation (Low-level laser/light therapy)

Typical parameters studiedWavelengths in trials often ~790–830 nm (infrared); reported power ranges 30–120 mW and energy density <30 J/cm2 in some studies/meta-analyses.

Intended mechanismLow-power light irradiation applied to salivary glands to stimulate salivary gland function and increase salivary flow.

Photo-biomodulation / LLLT — Evidence

DescriptionApplication of low-level light irradiation to salivary glands intended to improve salivary function.

Evidence summarySystematic reviews/meta-analyses reported short-term increases in unstimulated salivary flow (e.g., SMD 0.51 vs placebo, I2=50%) but effects on long-term quality-of-life are not demonstrated; randomized trial in primary Sjögren's (n=66) using an 808 nm protocol showed no benefit.

LimitationsHeterogeneous protocols, high risk of bias in many trials, and lack of standardized parameters limit definitive conclusions and sustained QOL benefit.

TENS / ALTENS — Evidence

TermTENS / ALTENS (Transcutaneous electrical nerve stimulation or acupuncture-like TENS)

Evidence summarySystematic reviews pool heterogeneous RCTs; one meta-analysis of 6 RCTs (369 participants) did not find a statistically significant pooled benefit for TENS on salivary flow (SMD 0.63 [-0.03 to 1.29]); RTOG 0537 (ALTENS) found no significant difference vs pilocarpine for the primary xerostomia endpoint at 9 months.

Notes on consistencySome individual studies reported increased saliva production during stimulation, but results are inconsistent across trials and optimal stimulation parameters remain unclear.

Topical sialogogue spray (1% malic acid)

InterventionTopical sialogogue spray containing 1% malic acid (gustatory topical spray)

Trial evidenceMeta-analysis of 5 trials (244 patients) of 2‑week courses found the malic acid 1% spray improved dry mouth symptoms (DMQ, XI, VAS) and increased unstimulated and stimulated saliva flow versus placebo.

LimitationsEvidence limited to short (2‑week) treatment courses; long-term efficacy and enamel/safety implications remain uncertain and require further RCTs with longer follow-up.